Epigenetic repression of transcription by the Vitamin D3 receptor in prostate cancer cells

Journal of Steroid Biochemistry and Molecular Biology

Volumn 89-90, Issue , 2004, Pages 251-256

  Gommersall, Lyndon M ^a   Khanim, Farhat L ^a   Peehl, Donna M ^b   Doherty, Alan H ^c   Campbell, Moray J ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

1 ,25 Dihydroxyvitamin D 3; Co repressors; Histone deacetylation inhibitors; Prostate cancer

Indexed keywords

CALCITRIOL; CELL NUCLEUS RECEPTOR; COLECALCIFEROL RECEPTOR; HISTONE DEACETYLASE INHIBITOR; NUCLEAR RECEPTOR COREPRESSOR; TRICHOSTATIN A; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL CULTURE; CELL ACTIVITY; CELL PROLIFERATION; CONFERENCE PAPER; CONTROLLED STUDY; DEACETYLATION; DRUG RESPONSE; EPIGENETICS; GENE CONTROL; GENE REPRESSION; GENE SEQUENCE; GENE TARGETING; HUMAN; HUMAN CELL; PROSTATE CANCER; PROTEIN EXPRESSION; RECEPTOR INTRINSIC ACTIVITY; TRANSCRIPTION REGULATION;

ACETYLTRANSFERASES; BASE SEQUENCE; CELL LINE, TUMOR; DNA PRIMERS; HISTONE ACETYLTRANSFERASES; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, CALCITRIOL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION, GENETIC;

EID: 3042598901     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2004.03.080     Document Type: Conference Paper

References (23)

1. Feldman B.J., Feldman D. The development of androgen-independent prostate cancer. Nat. Rev. Cancer. 1:2001;34-45
2. Mueller E., Smith M., Sarraf P., Kroll T., Aiyer A., Kaufman D.S., Oh W., Demetri G., Figg W.D., Zhou X.P., Eng C., Spiegelman B.M., Kantoff P.W. Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc. Natl. Acad. Sci. U.S.A. 97:2000;10990-10995
3. 3 analog. Endocrinology. 139:1998;1972-1980
4. Hanchette C.L., Schwartz G.G. Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer. 70:1992;2861-2869
5. Bell N.H., Greene A., Epstein S., Oexmann M.J., Shaw S., Shary J. Evidence for alteration of the Vitamin D-endocrine system in blacks. J. Clin. Invest. 76:1985;470-473
6. Ingles S.A., Haile R.W., Henderson B.E., Kolonel L.N., Nakaichi G., Shi C.Y., Yu M.C., Ross R.K., Coetzee G.A. Strength of linkage disequilibrium between two Vitamin D receptor markers in five ethnic groups: implications for association studies. Cancer Epidemiol. Biomarkers Prev. 6:1997;93-98
7. 3 on primary cultures of human prostatic cells. Cancer Res. 54:1994;805-810
8. Beer T.M., Lemmon D., Lowe B.A., Henner W.D. High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma. Cancer. 97(5):2003;1217-1224
9. 3 analogue involves the induction of p21waf1, p27kip1 and E-cadherin. J. Mol. Endocrinol. 19:1997;15-27
10. Zhuang S.H., Schwartz G.G., Cameron D., Burnstein K.L. Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of Vitamin D in human prostate cancer cell lines. Mol. Cell. Endocrinol. 126:1997;83-90
11. 3 receptor in bone. Mol. Carcinog. 19:1997;254-257
12. 3 in seven human prostatic carcinoma cell lines. Clin. Cancer Res. 1:1995;997-1003
13. 3 receptor-corepressor partnership. FASEB J. 14:2000;1455-1463
14. Guenther M.G., Barak O., Lazar M.A. The SMRT and N-CoR corepressors are activating cofactors for histone deacetylase 3. Mol. Cell. Biol. 21:2001;6091-6101
15. Tagami T., Lutz W.H., Kumar R., Jameson J.L. The interaction of the Vitamin D receptor with nuclear receptor corepressors and coactivators. Biochem. Biophys. Res. Commun. 18:1998;358-363
16. 3 receptor: a network of coactivator interactions. Gene. 246:2000;9-21
17. Baudino T.A., Kraichely D.M., Jefcoat S.C. Jr., Winchester S.K., Partridge N.C., MacDonald P.N. Isolation and characterization of a novel coactivator protein, NCoA-62, involved in Vitamin D-mediated transcription. J. Biol. Chem. 273:1998;16434-16441
18. Turner B.M. Histone acetylation and an epigenetic code. Bioessays. 22:2000;836-845
19. 3 and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A. Oncogene. 20:2001;1860-1872
20. Schmid H.P., McNeal J.E. An abbreviated standard procedure for accurate tumor volume estimation in prostate cancer. Am. J. Surg. Pathol. 16:1992;184-191
21. 3 and its analog EB1089 under growth-inhibitory conditions in squamous carcinoma cells. Mol. Endocrinol. 15:2001;1127-1139
22. Munster P.N., Troso-Sandoval T., Rosen N., Rifkind R., Marks P.A., Richon V.M. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res. 61:2001;8492-8497
23. D.M. Peehl, Growth of prostatic epithelial and stromal cells in vitro, Methods Mol. Med. 81 (2003) 41-57.